[HTML][HTML] Liver transplantation for hepatocellular carcinoma: management after the transplant
Hepatocellular carcinoma (HCC) is an increasingly common indication for liver
transplantation (LT) in the United States and in many parts of the world. In the last decade …
transplantation (LT) in the United States and in many parts of the world. In the last decade …
Prognostic role of selection criteria for liver transplantation in patients with hepatocellular carcinoma: a network meta-analysis
VJ Lozanovski, A Ramouz, E Aminizadeh… - BJS open, 2022 - academic.oup.com
Background Patients with hepatocellular carcinoma (HCC) are selected for transplantation if
they have a low tumour burden and low risk of recurrence. The morphometric Milan criteria …
they have a low tumour burden and low risk of recurrence. The morphometric Milan criteria …
[HTML][HTML] Up-to-seven criteria for hepatocellular carcinoma liver transplantation: a single center analysis
JY Lei, WT Wang, LN Yan - World Journal of Gastroenterology …, 2013 - ncbi.nlm.nih.gov
AIM: To detect whether the up-to-seven should be used as inclusion criteria for liver
transplantation for hepatocellular carcinoma. METHODS: Between April 2002 and July …
transplantation for hepatocellular carcinoma. METHODS: Between April 2002 and July …
Combination of morphologic criteria and α-fetoprotein in selection of patients with hepatocellular carcinoma for liver transplantation minimizes the problem of …
M Grąt, O Kornasiewicz, Z Lewandowski… - World Journal of …, 2014 - Springer
Background Serum α-fetoprotein concentration (AFP) might be a useful addition to
morphologic criteria for selecting patients with hepatocellular carcinoma (HCC) for liver …
morphologic criteria for selecting patients with hepatocellular carcinoma (HCC) for liver …
Alpha-fetoprotein level predicts recurrence after transplantation in hepatocellular carcinoma
L dos Santos Schraiber, AA de Mattos, ML Zanotelli… - Medicine, 2016 - journals.lww.com
Hepatocellular carcinoma (HCC) is one of the leading causes of liver transplantation. In an
attempt to predict their recurrence after liver transplantation, evaluation of tumor number and …
attempt to predict their recurrence after liver transplantation, evaluation of tumor number and …
Comparison of DEB-TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up-to-seven criteria: a single-center propensity score …
Q Shi, J Liu, T Li, C Zhou, Y Wang, S Huang… - Clinics and research in …, 2022 - Elsevier
Purpose To evaluate clinical outcomes of drug-eluting beads transarterial
chemoembolization (DEB-TACE) with CalliSpheres microspheres and conventional TACE …
chemoembolization (DEB-TACE) with CalliSpheres microspheres and conventional TACE …
Systemic therapy with or without transcatheter intra-arterial therapies for unresectable hepatocellular carcinoma: a real-world, multi-center study
Background Systemic therapy is the standard care of unresectable hepatocellular carcinoma
(uHCC), while transcatheter intra-arterial therapies (TRITs) were also widely applied to …
(uHCC), while transcatheter intra-arterial therapies (TRITs) were also widely applied to …
A changing etiologic scenario in liver transplantation for hepatocellular carcinoma in a multicenter cohort study from Latin America
Background and aim Non-alcoholic fatty liver disease (NAFLD) is an increasing cause of
hepatocellular carcinoma (HCC) and liver transplantation (LT). Our study focused on …
hepatocellular carcinoma (HCC) and liver transplantation (LT). Our study focused on …
[HTML][HTML] Expanding indications for liver transplant: tumor and patient factors
KKW Chu, KHC Wong, KSH Chok - Gut and Liver, 2021 - ncbi.nlm.nih.gov
During the past few decades, liver transplant has developed from a high-mortality procedure
to an almost routine procedure with good survival outcomes. The development of living …
to an almost routine procedure with good survival outcomes. The development of living …
[HTML][HTML] Downstaging disease in patients with hepatocellular carcinoma outside up-to-seven criteria: Strategies using degradable starch microspheres transcatheter …
A Orlacchio, F Chegai, S Merolla… - World Journal of …, 2015 - ncbi.nlm.nih.gov
AIM: To evaluate the downstaging rates in hepatitis C virus-patients with hepatocellular
carcinoma (HCC), treated with degradable starch microspheres transcatheter arterial …
carcinoma (HCC), treated with degradable starch microspheres transcatheter arterial …